



Genocea Biosciences  
Investor Relations Department  
100 Acom Park Drive, 5th Floor  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: GNCA

Last Trade:	1.16
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	0.00 (0.000%)
Day Range	1.13 - 1.21
52-Week Range	0.79 - 7.29
Volume	4,805,233

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Mar 12, 2018*  
[Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing](#)
- Mar 5, 2018*  
[Genocea to Present at Two March Investor Conferences](#)
- Feb 15, 2018*  
[Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results](#)
- Feb 12, 2018*  
[NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board of Directors](#)
- Feb 8, 2018*  
[Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET](#)

### Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 16, 2018*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*  
[Quarterly Report \(10-Q\)](#)